Radionuclide therapy with the second-generation Affibody molecule [188Re]Re-Z41071 improves survival in mice bearing human HER2-expressing xenografts

MLA

Yongsheng Liu, et al. “Radionuclide Therapy with the Second-Generation Affibody Molecule [188Re]Re-Z41071 Improves Survival in Mice Bearing Human HER2-Expressing Xenografts.” Nuclear Medicine and Biology, Nov. 2022, p. S27. EBSCOhost, https://doi.org/10.1016/s0969-8051(22)02147-3.

APA

Yongsheng Liu, Anzhelika Vorobyeva, Anna Orlova, Mark Konijnenberg, Tianqi Xu, Olga Bragina, Annika Loftenius, Erica Rosander, Fredrik Frejd, & Vladimir Tolmachev. (2022). Radionuclide therapy with the second-generation Affibody molecule [188Re]Re-Z41071 improves survival in mice bearing human HER2-expressing xenografts. Nuclear Medicine and Biology, S27. https://doi.org/10.1016/s0969-8051(22)02147-3

Chicago

Yongsheng Liu, Anzhelika Vorobyeva, Anna Orlova, Mark Konijnenberg, Tianqi Xu, Olga Bragina, Annika Loftenius, Erica Rosander, Fredrik Frejd, and Vladimir Tolmachev. 2022. “Radionuclide Therapy with the Second-Generation Affibody Molecule [188Re]Re-Z41071 Improves Survival in Mice Bearing Human HER2-Expressing Xenografts.” Nuclear Medicine and Biology, November, S27. doi:10.1016/s0969-8051(22)02147-3.